denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, Combination therapy, Therapies, therapy sequence, Minimal Residual Disease
Session: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, Combination therapy, Therapies, therapy sequence, Minimal Residual Disease
Sunday, December 10, 2023, 9:30 AM-10:45 AM
Disclosures: Hartley-Brown: Janssen: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; GlaskoSmith Kline: Consultancy, Honoraria; Bristol Myers Squibb/Celgene: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria.
OffLabel Disclosure:
See more of: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
See more of: Education Program
See more of: Education Program